People · Operator
Named in public records as an officer, director or promoter · active 2017–2018 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Polarityte, Inc. | — | Biotechnology | Series B | $24.0M | $69.4M | 2017 |
| SmartPharm Therapeutics, Inc. | — | Pharma | Series A | $10.5M | $326.0M | 2018 |
Jon Mogford at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jon Mogford on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steve Gorlin | 2 | 11 |
| John Thomas | 1 | 10 |
| MICHAEL CALLAHAN | 1 | 7 |
| MICHAEL BRAUSER | 1 | 6 |
| Barry Honig | 1 | 6 |
| John Stetson | 1 | 3 |
| Peter Cohen | 1 | 3 |
| Mohit Bhansali | 1 | 2 |
| Richard Hague | 1 | 2 |
| Jeff Dyer | 1 | 1 |
| Edward Swanson | 1 | 1 |
| Michael Neumeister | 1 | 1 |
| Timothy Brauns | 1 | 1 |
| Jose Trevejo | 1 | 1 |
| Chris Nolet | 1 | 1 |
| Jeffrey Dyer | 1 | 1 |
| Cameron Hoyler | 1 | 1 |
| Jacob Patterson | 1 | 1 |
| Denver Lough | 1 | 1 |
| David Seaburg | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.